Manufacturing Chemist: Paul Quigley on Accelerating your oncology clinical trials with Translational Pharmaceutics
Dr Paul Quigley, Quotient Sciences' Principal Research Fellow of Drug Substance, suggests that the nature of new molecular entities (NMEs) requires earlier delivery of a high-quality CMC package requiring a novel approach to accelerate the clinical trial process.
Paul's latest comments were featured in a Manufacturing Chemist feature entitled, "Accelerating your oncology clinical trials with Translational Pharmaceutics".
In this article, Paul discusses the need to reduce white space in the development process, which is where Quotient Sciences’ integrated Translational Pharmaceutics platform is uniquely positioned to help.
Read more of Paul's recent contribution to Manufacturing Chemist by following the link below.
Ask the Experts: Dr. Paul Quigley
You can connect directly with Paul, our scientific expert on Drug Substance directly, by clicking here.